Dynavax Technologies Corp (OQ:DVAX)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 2100 Powell Street, Suite 720 EMERYVILLE CA 94608 |
| Tel: | N/A |
| Website: | https://www.dynavax.com |
| IR: | See website |
| Key People | ||
| David F. Novack President, Chief Operating Officer | Ryan Spencer Chief Executive Officer, Interim Chief Financial Officer, Director | Robert Janssen Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs |
| Business Overview |
| Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older. |
| Financial Overview |
| For the three months ended 31 March 2024, Dynavax Technologies Corp revenues increased 8% to $50.8M. Net loss decreased 64% to $8.7M. Revenues reflect HEPLISAV-B segment increase of 10% to $47.8M. Lower net loss reflects Bad debt expense decrease from $12.3M (expense) to $0K, Interest income increase of 44% to $9.5M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.19 to -$0.07. |
| Employees: | 408 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $942.86M as of Mar 31, 2024 |
| Annual revenue (TTM): | $236.15M as of Mar 31, 2024 |
| EBITDA (TTM): | -$16.63M as of Mar 31, 2024 |
| Net annual income (TTM): | $9.22M as of Mar 31, 2024 |
| Free cash flow (TTM): | $52.69M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 130,891,710 as of May 6, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.